Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Wednesday morning. The brokerage issued a sell rating on the stock.

MBRX has been the subject of a number of other reports. Roth Mkm reiterated a buy rating and issued a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group dropped their price objective on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th.

Moleculin Biotech Trading Up 2.9 %

Shares of MBRX opened at $3.52 on Wednesday. Moleculin Biotech has a 52 week low of $3.21 and a 52 week high of $15.75. The firm’s 50-day simple moving average is $4.11 and its 200 day simple moving average is $5.90.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $1.57. On average, equities analysts forecast that Moleculin Biotech will post -8.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned approximately 9.60% of Moleculin Biotech at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.